Particulars of Complaint One
Patient A
1. Between 26 October 2017 to 13 September 2019, in the course of treating Patient A, the practitioner failed to properly assess Patient A prior to prescribing her with the Schedule 8 drugs Oxycontin and Fentanyl failing to:
1. take an appropriate history and perform an appropriate examination
2. ensure the practitioner had an appropriate clinical indication to prescribe a potential drug of dependence
3. explore Patient A's potential misuse of opioids having regard to the quantities of Oxycontin and Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner
4. consider urinary drug screening to assess disclosed or undisclosed drug use
5. offer alternative approaches to pain management such as the use of SSRs (selective serotonin reuptake inhibitors)
1. Between January 2019 to 13 September 2019 the practitioner failed to make timely referrals for specialist assistance when prescribing the Schedule 8 drug Oxycontin and Fentanyl.
2. Between 26 October 2017 to 13 September 2019 the practitioner's prescribing for Patient A of the Schedule 8 drugs Oxycontin and Fentanyl (as set out in Annexure A)
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the Poisons and Therapeutic Goods Regulation 2008 ('the PTGR')
2. otherwise was not clinically appropriate in the patient's circumstances, having regard to the quantities of Oxycontin and Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 26 October 2017 to 13 September 2019, the practitioner prescribed for Patient A the Schedule 8 drugs Oxycontin and Fentanyl as set out in Annexure A in circumstances which:
1. Oxycontin and Fentanyl were type C drugs of addiction within the meaning of section 28(6) of the PTGA
2. the practitioner should have known that Patient A was a drug seeking person
3. the practitioner did not obtain the proper authority from the Secretary of NSW Health.
4. on 13 September 2019 the practitioner prescribed the Schedule 8 drug Oxycontin when he was still waiting on an authority to be issued
contrary to section 28(3) of the PTGA.
1. Between 26 October 2017 to 13 September 2019, in the course of treating Patient A, the practitioner failed to recognise and respond appropriately to Patient A's drug seeking behaviour.
Patient B
1. Between 12 April 2017 to 15 April 2019, in the course of treating Patient B, the practitioner failed to properly assess Patient B prior to prescribing him with the Schedule 8 drugs Oxycontin and Fentanyl by failing to:
1. take an appropriate history and perform an appropriate examination
2. ensure the practitioner had an appropriate clinical indication to prescribe a potential drug of dependence
3. explore Patient B's use or potential misuse of opioids when providing the initial script
4. telephone and consult the Prescription Shopping Program
5. telephone and consult with the Drug and Alcohol Specialist Advisory Service (DASAS)
6. offer alternative approaches to pain management such as the use of SSRIs (selective serotonin reuptake inhibitors) until May 2019
7. consider alternatives such as physical therapies prior to issuing scripts
8. consider urinary drug screening to assess disclosed or undisclosed drug use.
1. Between 12 April 2017 to 15 April 2019 while treating Patient B the practitioner failed to make timely referrals for pain specialist assistance when prescribing the Schedule 8 drug Oxycontin and Fentanyl.
2. Between 12 April 2017 to 15 April 2019, the practitioner's prescribing for Patient B of the Schedule 8 drugs Oxycontin and Fentanyl as set out in Annexure B:
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
2. otherwise was not clinically appropriate in the patient's circumstances;
having regard to the quantities of Oxycontin and Fentanyl the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 12 April 2017 to 15 April 2019, the practitioner prescribed for Patient B the Schedule 8 drugs Oxycontin and Fentanyl as set out in Annexure B in circumstances which
1. Oxycontin and Fentanyl were type C drugs of addiction within the meaning of section 28(6) of the PTGA;
2. the practitioner should have known that Patient B was a drug seeking person;
3. the practitioner did not obtain the proper authority from the Secretary of NSW Health;
contrary to section 28(3) of the PTGA.
1. Between 12 April 2017 to 15 April 2019, in the course of treating Patient B, the practitioner failed to recognise and respond appropriately to Patient B's drug seeking behaviour.
Patient C
1. Between 11 January 2017 to 21 March 2019, in the course of treating Patient C, the practitioner failed to properly assess Patient C prior to prescribing him with the Schedule 8 drugs Fentanyl and Targin by failing to:
1. take an appropriate history and perform an appropriate examination
2. ensure the practitioner had an appropriate clinical indication to prescribe a potential drug of dependence
3. explore Patient C's use and potential misuse of opioids through targeted questioning of Patient C
4. telephone and consult the Prescription Shopping Program
5. telephone and consult with the Drug and Alcohol Specialist Advisory Service (DASAS)
6. consider alternatives such as physical therapies or psychological therapies prior to issuing scripts
7. failed to consider urinary drug screening to assess disclosed or undisclosed drug use.
Between 11 January 2017 to 21 March 2019 while treating Patient C the practitioner failed to make timely referrals for specialist assistance when prescribing the Schedule 8 drugs Targin and Fentanyl.
1. Between 11 January 2017 to 21 March 2019 the practitioner's prescribing for Patient C of the Schedule 8 drug Fentanyl as set out in Annexure C:
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
2. otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 11 January 2017 to 21 March 2019, the practitioner prescribed for Patient C the Schedule 8 drugs Targin and Fentanyl as set out in Annexure C in circumstances which:
(d) Targin and Fentanyl were type C drugs of addiction within the meaning of section 28(6) of the PTGA
(e) the practitioner should have known that Patient C was a drug seeking person
(f) the practitioner did not obtain the proper authority from the Secretary of NSW Health
contrary to section 28(3) of the PTGA.
1. From 23 March 2018, the practitioner inappropriately continued to prescribe the Schedule 8 drug Fentanyl to Patient C after he received a warning from the Pharmaceutical Regulatory Unit not to prescribe.
2. Between 31 October 2018 to 21 March 2019, the practitioner inappropriately continued to prescribe the Schedule 8 drug Fentanyl to Patient C, despite receiving Patient C's medical records from the Griffith practice on 31 October 2018 which recorded that Schedule 8 drugs should not be prescribed to Patient C.
3. Between 11 January 2017 to 21 March 2019, in the course of treating Patient C, the practitioner failed to recognise and respond appropriately to Patient C's drug seeking behaviour.
Patient D
1. Between 19 August 2016 to 8 December 2017, in the course of treating Patient D, the practitioner failed to properly assess Patient D prior to prescribing him with the Schedule 8 drug Fentanyl by failing to:
1. take an appropriate history and perform an appropriate examination
2. ensure he had an appropriate clinical indication to prescribe a potential drug of dependence
3. explore Patient D's potential misuse of opioids when giving the initial script
4. telephone and consult the Prescription Shopping Program
5. telephone and consult with the Drug and Alcohol Specialist Advisory Service (DASAS)
6. consider alternatives such as physical therapies prior to issuing scripts
7. prepare a chronic pain management plan
8. consider urinary drug screening to assess disclosed or undisclosed drug use.
1. Between 19 August 2016 to 8 December 2017, while treating Patient D the practitioner failed to make timely referrals for specialist assistance focused on comprehensive pain management such as a pain specialist, when prescribing the Schedule 8 drug Fentanyl to Patient D.
2. Between 19 August 2016 to December 2017, the practitioner's prescribing for Patient D of the Schedule 8 drug Fentanyl as set out in Annexure D:
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
2. otherwise was not clinically appropriate in the patient's circumstances
having regard to the quantities of Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 19 August 2016 to 8 December 2017, the practitioner prescribed for Patient B the Schedule 8 drug Fentanyl as set out in Annexure D in circumstances which:
1. Fentanyl is a type C drug of addiction within the meaning of section 28(6) of the PTGA
2. the practitioner should have known that Patient C was a drug seeking person;
3. the practitioner did not obtain the proper authority from the Secretary of NSW Health
contrary to section 28(3) of the PTGA.
1. Between 19 August 2016 to 8 December 2017 in the course of treating Patient D, the practitioner failed to recognise and respond appropriately to Patient D's drug seeking behaviour.
Patient E
1. Between 7 June 2017 to 7 January 2019, in the course of treating Patient D, the practitioner failed to properly assess Patient E prior to prescribing him with the Schedule 8 drug Fentanyl by failing to:
1. take an appropriate history and perform an appropriate examination.
2. telephone and consult the Prescription Shopping Program.
3. telephone and consult with the Drug and Alcohol Specialist Advisory Service (DASAS).
4. consider alternatives such as physical therapies prior to issuing scripts.
1. Between 7 June 2017 to 7 January 2019, the practitioner's prescribing for Patient E of the Schedule 8 drug Fentanyl as set out in Annexure E:
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR:
2. otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 7 June 2017 to 7 January 2019, the practitioner prescribed for Patient E the Schedule 8 drug Fentanyl as set out in Annexure E in circumstances which:
1. Fentanyl is a type C drug of addiction within the meaning of section 28(6) of the PTGA;
2. The practitioner should have known that Patient E was a drug seeking person;
3. The practitioner did not obtain the proper authority from the Secretary of NSW Health
contrary to section 28(3) of the PTGA.
1. Between 7 June 2017 to 7 January 2019 in the course of treating Patient E, the practitioner failed to recognise and respond appropriately to Patient E's drug seeking behaviour.
2. Between 7 June 2018 to 7 January 2019 in the course of treating Patient E the practitioner failed to make enquiries with Victoria Health to determine if Patient E was subject to a Schedule 8 permit before prescribing him schedule 8 drugs.
Patient F
1. Between 24 November 2016 to 27 March 2019, in the course of treating Patient F, the practitioner failed to properly assess Patient F prior to prescribing him with the Schedule 8 Fentanyl by failing to:
1. take an appropriate history and perform an appropriate examination.
2. telephone and consult the Prescription Shopping Program.
3. telephone and consult with the Drug and Alcohol Specialist Advisory Service (DASAS).
4. ascertain from the medical records obtained from Matthew Talbot that Patient F was on an opioid replacement program and to take this into account this when prescribing.
1. Between 24 November 2016 to 27 Mach 2019, while treating Patient F, the practitioner failed to make timely referrals with references to the clinical use of opioids when prescribing the Schedule 8 drug Fentanyl to Patient F at the Gladesville practice.
2. Between 24 November 2016 to 27 March 2019, the practitioner's prescribing for Patient F of the Schedule 8 drug Fentanyl as set out in Annexure F:
1. did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
2. otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of Fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
1. Between 24 November 2016 to 27 March 2019, the practitioner prescribed for Patient F the Schedule 8 drug Fentanyl as set out in Annexure F in circumstances which:
1. Fentanyl is a type C drug of addiction within the meaning of section 28(6) of the PTGA;
2. the practitioner should have known that Patient F was a drug seeking person;
3. the practitioner did not obtain the proper authority from the Secretary of NSW Health
contrary to section 28(3) of the PTGA.
1. Between 24 November 2016 to 27 March 2019 in the course of treating Patient F, the practitioner failed to recognise and respond appropriately to Patient F's drug seeking behaviour.